Millennium Management
ADAP

Millennium Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Millennium Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-94,283
Closed -$18.6K – 5813
2025
Q1 		$18.6K Buy
94,283
+64,724
+219% +$33.5K ﹤0.01% 5637
2024
Q4 		$15.9K Sell
29,559
-685,791
-96% -$500K ﹤0.01% 5739
2024
Q3 		$680K Sell
715,350
-64,265
-8% -$72.9K ﹤0.01% 4581
2024
Q2 		$760K Sell
779,615
-45,564
-6% -$50K ﹤0.01% 4309
2024
Q1 		$1.3M Buy
825,179
+384,147
+87% +$464K ﹤0.01% 4079
2023
Q4 		$350K Buy
441,032
+140,971
+47% +$79.5K ﹤0.01% 4877
2023
Q3 		$234K Sell
300,061
-351,901
-54% -$295K ﹤0.01% 5038
2023
Q2 		$603K Buy
651,962
+352,370
+118% +$420K ﹤0.01% 4409
2023
Q1 		$327K Buy
299,592
+134,933
+82% +$209K ﹤0.01% 4852
2022
Q4 		$240K Buy
164,659
+153,255
+1,344% +$248K ﹤0.01% 5223
2022
Q3 		$12K Sell
11,404
-110,718
-91% -$203K ﹤0.01% 6602
2022
Q2 		$208K Sell
122,122
-1,325,492
-92% -$2.28M ﹤0.01% 5613
2022
Q1 		$2.98M Sell
1,447,614
-195,864
-12% -$529K ﹤0.01% 3502
2021
Q4 		$6.16M Buy
1,643,478
+58,629
+4% +$267K ﹤0.01% 2681
2021
Q3 		$8.19M Buy
1,584,849
+654,434
+70% +$2.94M ﹤0.01% 2320
2021
Q2 		$3.96M Sell
930,415
-686,118
-42% -$3.33M ﹤0.01% 3071
2021
Q1 		$8.58M Sell
1,616,533
-111,023
-6% -$636K 0.01% 1956
2020
Q4 		$9.31M Buy
1,727,556
+1,022,800
+145% +$5.56M 0.01% 1812
2020
Q3 		$5.62K Sell
704,756
-1,082,848
-61% -$9.48M 0.01% 1729
2020
Q2 		$17.9M Buy
1,787,604
+331,725
+23% +$2.08M 0.02% 806
2020
Q1 		$3.96M Buy
1,455,879
+962,644
+195% +$3.19M 0.01% 1505
2019
Q4 		$592K Sell
493,235
-421,181
-46% -$449K ﹤0.01% 3284
2019
Q3 		$1.38M Sell
914,416
-404,876
-31% -$946K ﹤0.01% 2667
2019
Q2 		$5.3M Sell
1,319,292
-1,269,448
-49% -$5.18M 0.01% 1724
2019
Q1 		$11.1M Buy
2,588,740
+490,468
+23% +$2.28M 0.02% 1171
2018
Q4 		$12.1M Sell
2,098,272
-74,376
-3% -$549K 0.02% 1013
2018
Q3 		$29.5M Buy
2,172,648
+1,323,793
+156% +$13.9M 0.04% 643
2018
Q2 		$10.1M Sell
848,855
-628,786
-43% -$7.84M 0.01% 1308
2018
Q1 		$16.6M Buy
1,477,641
+672,046
+83% +$5.88M 0.02% 997
2017
Q4 		$5.38M Buy
805,595
+215,439
+37% +$1.66M 0.01% 1710
2017
Q3 		$4.83M Buy
590,156
+342,329
+138% +$2.14M 0.01% 1696
2017
Q2 		$1.11M Sell
247,827
-472,226
-66% -$2.47M ﹤0.01% 2393
2017
Q1 		$3.97M Buy
720,053
+48,393
+7% +$212K 0.01% 1588
2016
Q4 		$2.72M Buy
671,660
+25,170
+4% +$121K 0.01% 1699
2016
Q3 		$4.56M Sell
646,490
-28,348
-4% -$216K 0.01% 1391
2016
Q2 		$5.5M Sell
674,838
-241,784
-26% -$2.28M 0.01% 1201
2016
Q1 		$7.45M Buy
916,622
+572,075
+166% +$4.68M 0.02% 1012
2015
Q4 		$4.16M Buy
344,547
+156,724
+83% +$1.53M 0.01% 1487
2015
Q3 		$2.25M Buy
187,823
+70,006
+59% +$989K ﹤0.01% 1825
2015
Q2 		$2.16M Buy
+117,817
New +$2.02M ﹤0.01% 1872

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management's ADAP Position: Q2 2025 in Review

Millennium Management sold out of Adaptimmune Therapeutics (ADAP) in Q2 2025, closing a stake of 94,283 shares — an estimated $18.6K sold.

Millennium Management first reported a position in ADAP in Q2 2015 and held it in 40 quarters. The position peaked at $29.5M in Q3 2018. 65 funds tracked by Wall St. Rank hold ADAP as of Q2 2025.

  • Millennium Management reported no remaining Adaptimmune Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Millennium Management sold 94,283 Adaptimmune Therapeutics shares in Q2 2025, an estimated $18.6K.
  • Millennium Management first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 40 quarters.
  • Millennium Management's Adaptimmune Therapeutics position peaked at $29.5M in Q3 2018.
  • 65 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2025.

Based on Millennium Management's 13F filing for Q2 2025, filed 14 Aug 2025.